These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27003514)

  • 1. The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells.
    Zhao Z; Chen S; Zhu X; Pan F; Li R; Zhou Y; Yuan W; Ni H; Yang FC; Xu M
    Leukemia; 2016 Aug; 30(8):1784-1788. PubMed ID: 27003514
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.
    Ito K; Lee J; Chrysanthou S; Zhao Y; Josephs K; Sato H; Teruya-Feldstein J; Zheng D; Dawlaty MM; Ito K
    Cell Rep; 2019 Sep; 28(10):2480-2490.e4. PubMed ID: 31484061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
    Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
    Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.
    Li Z; Cai X; Cai CL; Wang J; Zhang W; Petersen BE; Yang FC; Xu M
    Blood; 2011 Oct; 118(17):4509-18. PubMed ID: 21803851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TET2 Loss Dysregulates the Behavior of Bone Marrow Mesenchymal Stromal Cells and Accelerates Tet2
    Li R; Zhou Y; Cao Z; Liu L; Wang J; Chen Z; Xing W; Chen S; Bai J; Yuan W; Cheng T; Xu M; Yang FC; Zhao Z
    Stem Cell Reports; 2018 Jan; 10(1):166-179. PubMed ID: 29290626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.
    Schaub FX; Lehmann T; Looser R; Hao-Shen H; Tichelli A; Skoda RC
    Blood; 2011 Feb; 117(6):2075-6. PubMed ID: 21310937
    [No Abstract]   [Full Text] [Related]  

  • 7. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.
    Song SJ; Ito K; Ala U; Kats L; Webster K; Sun SM; Jongen-Lavrencic M; Manova-Todorova K; Teruya-Feldstein J; Avigan DE; Delwel R; Pandolfi PP
    Cell Stem Cell; 2013 Jul; 13(1):87-101. PubMed ID: 23827711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [TET2 as a gatekeeper for hematologic malignancies].
    Muto H; Sakata-Yanagimoto M; Chiba S
    Rinsho Ketsueki; 2015 Jun; 56(6):651-6. PubMed ID: 26256875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TET2: epigenetic safeguard for HSC.
    Ko M; Rao A
    Blood; 2011 Oct; 118(17):4501-3. PubMed ID: 22033942
    [No Abstract]   [Full Text] [Related]  

  • 10. Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.
    Inoue S; Li WY; Tseng A; Beerman I; Elia AJ; Bendall SC; Lemonnier F; Kron KJ; Cescon DW; Hao Z; Lind EF; Takayama N; Planello AC; Shen SY; Shih AH; Larsen DM; Li Q; Snow BE; Wakeham A; Haight J; Gorrini C; Bassi C; Thu KL; Murakami K; Elford AR; Ueda T; Straley K; Yen KE; Melino G; Cimmino L; Aifantis I; Levine RL; De Carvalho DD; Lupien M; Rossi DJ; Nolan GP; Cairns RA; Mak TW
    Cancer Cell; 2016 Aug; 30(2):337-348. PubMed ID: 27424808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of TET2 in hematologic malignancies.
    Chiba S
    Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness.
    Ostrander EL; Kramer AC; Mallaney C; Celik H; Koh WK; Fairchild J; Haussler E; Zhang CRC; Challen GA
    Stem Cell Reports; 2020 Apr; 14(4):551-560. PubMed ID: 32220332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies.
    Li R; Xu MJ; Yang FC; Zhou Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):583-588. PubMed ID: 27825418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Functional analysis of TET2 using a knockdown mouse model].
    Shide K; Kameda T; Shimoda K
    Rinsho Ketsueki; 2015 Jun; 56(6):657-65. PubMed ID: 26256876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TET2 interactors and their links to hematological malignancies.
    Pan F; Weeks O; Yang FC; Xu M
    IUBMB Life; 2015 Jun; 67(6):438-45. PubMed ID: 26099018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
    Tefferi A; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Patnaik MM; Hanson CA; Pardanani A; Gilliland DG; Levine RL
    Leukemia; 2009 Jul; 23(7):1343-5. PubMed ID: 19295549
    [No Abstract]   [Full Text] [Related]  

  • 17. SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.
    Sun J; He X; Zhu Y; Ding Z; Dong H; Feng Y; Du J; Wang H; Wu X; Zhang L; Yu X; Lin A; McDonald T; Zhao D; Wu H; Hua WK; Zhang B; Feng L; Tohyama K; Bhatia R; Oberdoerffer P; Chung YJ; Aplan PD; Boultwood J; Pellagatti A; Khaled S; Kortylewski M; Pichiorri F; Kuo YH; Carlesso N; Marcucci G; Jin H; Li L
    Cell Stem Cell; 2018 Sep; 23(3):355-369.e9. PubMed ID: 30146412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF-mutant hematopoietic malignancies.
    Abdel-Wahab O; Park CY
    Oncotarget; 2014 Sep; 5(18):7980-1. PubMed ID: 25478626
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis.
    Cai Z; Kotzin JJ; Ramdas B; Chen S; Nelanuthala S; Palam LR; Pandey R; Mali RS; Liu Y; Kelley MR; Sandusky G; Mohseni M; Williams A; Henao-Mejia J; Kapur R
    Cell Stem Cell; 2018 Dec; 23(6):833-849.e5. PubMed ID: 30526882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In cauda venenum or the importance of TET(2)].
    Mercher T; Quivoron C; Couronné L; Vainchenker W; Bastard C; Bernard OA
    Med Sci (Paris); 2011 Dec; 27(12):1064-6. PubMed ID: 22192742
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.